•
Sep 30, 2024
Novocure Q3 2024 Earnings Report
Novocure experienced revenue growth and strategic advancements.
Key Takeaways
Novocure reported a 22% year-over-year increase in net revenues, reaching $155.1 million for the third quarter of 2024. The company also secured FDA approval for Optune Lua and saw significant growth across major markets, while solidifying its management team.
Net revenues for the quarter reached $155.1 million, a 22% increase compared to the same period in 2023.
FDA approved Optune Lua for the treatment of patients with metastatic non-small cell lung cancer.
The company received 1,586 prescriptions in the quarter, an increase of 8% compared to the same period in 2023.
As of September 30, 2024, there were 4,113 active patients on therapy.
Novocure
Novocure
Forward Guidance
Novocure anticipates several clinical milestones.
Positive Outlook
- Top-line data from Phase 3 PANOVA-3 clinical trial in locally advanced pancreatic cancer (Q4 2024)
- Data from Phase 2 PANOVA-4 clinical trial in metastatic pancreatic cancer (2026)
- Data from Phase 3 TRIDENT clinical trial in newly diagnosed glioblastoma (2026)
- Breakthrough Device designation gives us more frequent, faster and interactive access to the FDA review team and senior management during the review process
- Priority review of our marketing application upon filing, and expedited review of pre-PMA manufacturing and quality systems compliance inspections.